Filter News
Area of Research
News Topics
- (-) Biomedical (2)
- (-) Materials Science (3)
- (-) Physics (2)
- (-) Security (1)
- Artificial Intelligence (1)
- Biology (1)
- Computer Science (3)
- Coronavirus (1)
- Cybersecurity (2)
- Environment (2)
- Fusion (1)
- Machine Learning (1)
- Materials (1)
- Nanotechnology (1)
- National Security (1)
- Neutron Science (12)
- Quantum Science (1)
Media Contacts
ASM International recently elected three researchers from ORNL as 2021 fellows. Selected were Beth Armstrong and Govindarajan Muralidharan, both from ORNL’s Material Sciences and Technology Division, and Andrew Payzant from the Neutron Scattering Division.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
The COHERENT particle physics experiment at the Department of Energy’s Oak Ridge National Laboratory has firmly established the existence of a new kind of neutrino interaction.
IDEMIA Identity & Security USA has licensed an advanced optical array developed at Oak Ridge National Laboratory. The portable technology can be used to help identify individuals in challenging outdoor conditions.
An ORNL-led team's observation of certain crystalline ice phases challenges accepted theories about super-cooled water and non-crystalline ice. Their findings, reported in the journal Nature, will also lead to better understanding of ice and its various phases found on other planets, moons and elsewhere in space.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.